Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what’s the evidence?

References

• Felson DT. An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin North Am 2004;42:1-9
   PubMed Web of Science ®Google Scholar
• Issa SN, Sharma L. Epidemiology of osteoarthritis: an update. Curr Rheumatol Rep 2006;8:7-15
   PubMedGoogle Scholar
• Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99
   PubMed Web of Science ®Google Scholar
• Pereira D, Peleteiro B, Araujo J, et al. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage 2011;19:1270-85
   PubMed Web of Science ®Google Scholar
• Wieland HA, Michaelis M, Kirschbaum BJ, et al. Osteoarthritis – an untreatable disease? Nat Rev Drug Discov 2005;4:331-44
   PubMed Web of Science ®Google Scholar
• Lane NE, Brandt K, Hawker G, et al. OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cartilage 2011;19:478-82
   PubMed Web of Science ®Google Scholar
• Eyre DR. Collagens and cartilage matrix homeostasis. Clin Orthop Relat Res 2004;427(Suppl):S118-22
   PubMed Web of Science ®Google Scholar
• Guccione AA, Felson DT, Anderson JJ, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health 1994;84:351
   PubMed Web of Science ®Google Scholar
• Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 2001;60:91-7
   PubMed Web of Science ®Google Scholar
• Linaker CH, Walker-Bone K, Palmer K, et al. Frequency and impact of regional musculoskeletal disorders. Baillieres Best Pract Res Clin Rheumatol 1999;13:197-215
   PubMed Web of Science ®Google Scholar
• Walsh DA, McWilliams DF, Turley MJ, et al. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford) 2010;49:1852-61
   PubMed Web of Science ®Google Scholar
• Kidd BL, Photiou A, Inglis JJ. The role of inflammatory mediators on nociception and pain in arthritis. Novartis Found Symp 2004;260:122-33; discussion 133-8, 277-9
   PubMedGoogle Scholar
• Dieppe, P, Lohmander, L. Pathogenesis and management of pain in osteoarthritis. Lancet 2005;365:965-73
   PubMed Web of Science ®Google Scholar
• Roemer FW, Frobell R, Hunter DJ, et al. MRI-detected subchondral bone marrow signal alterations of the knee joint: terminology, imaging appearance, relevance and radiological differential diagnosis. Osteoarthritis Cartilage 2009;17:1115-31
   PubMed Web of Science ®Google Scholar
• Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49
   PubMed Web of Science ®Google Scholar
• Hunter D, Gerstenfeld L, Bishop G, et al. Bone marrow lesions from osteoarthritis knees are characterized by sclerotic bone that is less well mineralized. Arthritis Res Ther 2009;11:R11
   PubMed Web of Science ®Google Scholar
• Hunter, D. Risk stratification for knee osteoarthritis progression: a narrative review. Osteoarthritis Cartilage 2009;17:1402-7
   PubMed Web of Science ®Google Scholar
• Naredo E, Cabero F, Palop MJ, et al. Ultrasonographic findings in knee osteoarthritis: a comparative study with clinical and radiographic assessment. Osteoarthritis Cartilage 2005;13:568-74
   PubMed Web of Science ®Google Scholar
• Hunter D. Pharmacologic therapy for osteoarthritis-the era of disease modification. Nat Rev Rheumatol 2011;7:13-22
   PubMed Web of Science ®Google Scholar
• Wildi LM, Raynauld JP, Martel-Pelletier J, et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011;70:982-9
   PubMed Web of Science ®Google Scholar
• Gabay C, Medinger-Sadowski C, Gascon D, et al. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum 2011;63:3383-91
   PubMed Web of Science ®Google Scholar
• Möller I, Pérez M, Monfort J, et al. Effectiveness of chondroitin sulfate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage 2010;18(Suppl 1):S32-40
   PubMed Web of Science ®Google Scholar
• Rainsford KD. Importance of pharmaceutical composition and evidence from clinical trials and pharmacological studies in determining effectiveness of chondroitin sulfate and other glycosaminoglycans: a critique. J Pharm Pharmacol 2009;6:1263-70
   Google Scholar
• Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:524-33
   PubMed Web of Science ®Google Scholar
• Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005;52:779-86
   PubMed Web of Science ®Google Scholar
• Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004;12:269-76
   PubMed Web of Science ®Google Scholar
• Verbruggen G, Goemaere S, Veys EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol 2002;21:231-43
   PubMed Web of Science ®Google Scholar
• Leeb BF, Schweitzer H, Montag K, et al. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205-11
   PubMed Web of Science ®Google Scholar
• McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283:1469-75
   PubMed Web of Science ®Google Scholar
• Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee OA. Osteoarthritis Cartilage 1998;6(Suppl A):31-6
   PubMed Web of Science ®Google Scholar
• Uebelhart D, Thonar EJ, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998;6(Suppl A):39-46
   PubMed Web of Science ®Google Scholar
• Morreale P, Manopulo R, Galati M, et al. Comparison of the anti-inflammatory efficacy of CS and diclofenac sodium in patients with knee OA. J Rheumatol 1996;23:1385-91
   PubMed Web of Science ®Google Scholar
• Conrozier T, Vignon E. Effects of chondroitin sulfate in the treatment of coxarthrosis. A double-blind study versus placebo [Article in French]. Litera Rheumatologica 1992;14:69-75
   Google Scholar
• Tat SK, Pelletier JP, Mineau F, et al. Variable effects of 3 different chondroitin sulfate compounds on human osteoarthritic cartilage/chondrocytes: relevance of purity and production process. J Rheumatol 2010;37:656-64
   PubMed Web of Science ®Google Scholar
• Calamia V, Fernández-Puente P, Mateos J, et al. Pharmacoproteomic study of three different chondroitin sulfate compounds on intracellular and extracellular human chondrocyte proteomes. Mol Cell Proteomics 2012;11:M111.013417. Epub 2011 Dec 27.
   PubMed Web of Science ®Google Scholar
• Volpi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol 2009;61:1271-80
   PubMed Web of Science ®Google Scholar
• Volpi N. Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci 2007;96:3168-80
   PubMed Web of Science ®Google Scholar
• Volpi N, Maccari F. Two analytical approaches to the evaluation of chondroitin sulfate in European food supplements. Separation Sci 2009;1:23-8
   Google Scholar
• Wang L, Wang J, Almqvist KF, et al. Influence of polysulfated polysaccharides and hydrocortisone on the extracellular matrix metabolism of human articular chondrocytes in vitro. Clin Exp Rheumatol 2002;20:669-76
   PubMed Web of Science ®Google Scholar
• Bassleer CT, Combal JP, Bougaret S, et al. Effects of chondroitin sulfate and interleukin-1 beta on human articular chondrocytes cultivated in clusters. Osteoarthritis Cartilage 1998;6:196-204
   PubMed Web of Science ®Google Scholar
• Legendre F, Bauge C, Roche R, et al. Chondroitin sulfate modulation of matrix and inflammatory gene expression in IL-1beta-stimulated chondrocytes—study in hypoxic alginate bead cultures. Osteoarthritis Cartilage 2008;16:105-14
   PubMed Web of Science ®Google Scholar
• Imada K, Oka H, Kawasaki D, et al. Anti-arthritic action mechanisms of natural chondroitin sulfate in human articular chondrocytes and synovial fibroblasts. Biol Pharm Bull 2010;33:410-14
   PubMed Web of Science ®Google Scholar
• Tahiri K, Korwin-Zmijowska K, Richette P, et al. Natural chondroitin sulfates increase aggregation of proteoglycan complexes and decrease ADAMTS-5 expression in interleukin 1 beta-treated chondrocytes. Ann Rheum Dis 2008;67:696-702
   PubMed Web of Science ®Google Scholar
• Chan PS, Caron JP, Orth MW. Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants. Am J Vet Res 2005;66:1870-6
   PubMed Web of Science ®Google Scholar
• Monfort J, Nacher M, Montell E, et al. Chondroitin sulfate and hyaluronic acid (500–730 kDa) inhibit stromelysin-1 synthesis in human osteoarthritic chondrocytes. Drugs Exp Clin Res 2005;31:71-6
   PubMedGoogle Scholar
• Jomphe C, Gabriac M, Hale TM, et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes. Basic Clin Pharmacol Toxicol 2008;102:59-65
   PubMed Web of Science ®Google Scholar
• Campo GM, Avenoso A, Campo S, et al. Glycosaminoglycans modulate inflammation and apoptosis in LPS-treated chondrocytes. J Cell Biochem 2009;106:83-92
   PubMed Web of Science ®Google Scholar
• Vallières M and du Souich P. Modulation of inflammation by chondroitin sulfate. Osteoarthritis Cartilage 2010;18(Suppl 1):S1-6
   PubMed Web of Science ®Google Scholar
• Campo GM, Avenoso A, Campo S, et al. Chondroitin-4 sulphate inhibits NF-kB translocation and caspase activation in collagen-induced arthritis in mice. Osteoarthritis Cartilage 2008;16:1474-83
   PubMed Web of Science ®Google Scholar
• Domagala F, Martin G, Bogdanowicz P, et al. Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1: potential mechanism for Diacerein effects in osteoarthritis. Biorheology 2006;43:577-87
   PubMed Web of Science ®Google Scholar
• Roman-Blas JA, Jimenez SA. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2006;14:839-48
   PubMed Web of Science ®Google Scholar
• Agarwal S, Deschner J, Long P, et al. Role of NF-kappaB transcription factors in antiinflammatory and proinflammatory actions of mechanical signals. Arthritis Rheum 2004;50:3541-8
   PubMed Web of Science ®Google Scholar
• Taniguchi S, Ryu J, Seki M, et al. Long-term oral administration of glucosamine or chondroitin sulfate reduces destruction of cartilage and up-regulation of MMP-3 mRNA in a model of spontaneous osteoarthritis in Hartley guinea pigs. J Orthop Res 2012;30:673-8
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Mori I, Umemoto J. Influences of sulfated glycosaminoglycans on biosynthesis of hyaluronic acid in rabbit knee synovial membrane. Arch Biochem Biophys 1985;240:146-53
   PubMed Web of Science ®Google Scholar
• Volpi N. Anti-inflammatory activity of chondroitin sulfate: new functions from an old natural macromolecule. Inflammopharmacology 2011;19:299-306
   PubMedGoogle Scholar
• Du Souich P. Immunomodulatory and anti-inflammatory effects of chondroitin sulfate. Eur Musculoskeletal Rev 2009;4:8-10
   Google Scholar
• Campo GM, Avenoso A, Campo S, et al. Glycosaminoglycans reduced inflammatory response by modulating toll-like receptor-4 in LPS-stimulated chondrocytes. Arch Biochem Biophys 2009;491:7-15
   PubMed Web of Science ®Google Scholar
• Henrotin Y, Mathy M, Sanchez C, et al. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Ther Adv Musculoskel Dis 2010;2:335-48
   PubMedGoogle Scholar
• David-Raoudi M, Deschreve B, Leclercq S, et al. Chondroitin sulfate increases hyaluronan production by human synoviocytes through differential regulation of hyaluronan synthases. Arthritis Rheum 2009;60:760-70
   PubMed Web of Science ®Google Scholar
• Omata T, Itokazu Y, Inoue N, et al. Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis. Arzneimittelforschung 2000;50:148-53
   PubMed Web of Science ®Google Scholar
• Cho SY, Sim JS, Jeong CS, et al. Effects of low molecular weight chondroitin sulfate on type II collagen-induced arthritis in DBA/1J mice. Biol Pharm Bull 2004;27:47-51
   PubMed Web of Science ®Google Scholar
• Li X, Makarov SS. An essential role of NF-kappaB in the "tumor-like" phenotype of arthritic synoviocytes. Proc Natl Acad Sci U S A 2006;103:17432-7
   PubMed Web of Science ®Google Scholar
• Tas SW, Hajji N, Stenvers DJ, et al. Reduction of proinflammatory cytokine expression in the synovium by targeting IKKbeta in vivo in a rat model. Arthritis Rheum 2006;54:3716-18
   PubMed Web of Science ®Google Scholar
• Lambert C, Mathy-Hartert M, Dubuc JE, et al. Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Res Ther 2012;14:R58
   PubMed Web of Science ®Google Scholar
• Tat SK, Pelletier JP, Vergés J, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Res Ther 2007;9:R117
   PubMed Web of Science ®Google Scholar
• Tsubaki M, Kato C, Manno M, et al. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways. Mol Cell Biochem 2007;304:53-60
   PubMed Web of Science ®Google Scholar
• Pecchi E, Priam S, Mladenovic Z, et al. A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E2 and matrix metalloproteinases synthesis in interleukin-1β-stimulated osteoblasts. Osteoarthritis Cartilage 2012;20:127-35
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacological and pharmacological therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64:465-74
   PubMed Web of Science ®Google Scholar
• Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010;18:476-99
   PubMed Web of Science ®Google Scholar
• Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62
   PubMed Web of Science ®Google Scholar
• Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007;15:981-1000
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:377-88
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81
   PubMed Web of Science ®Google Scholar
• Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55
   PubMed Web of Science ®Google Scholar
• Read SJ, Dray A. Osteoarthritic pain: a review of current, theoretical and emerging therapeutics. Expert Opin Investig Drugs 2008;17:619-40
   PubMed Web of Science ®Google Scholar
• Bjordal JM, Klovning A, Ljunggren AE, et al. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007;11:125-38
   PubMed Web of Science ®Google Scholar
• Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010;341:c4675
   PubMed Web of Science ®Google Scholar
• Pelletier JP, Hochberg MC, du Souich P, et al. Glucosamine and osteoarthritis. Effect size is encouraging. BMJ 2010;341:c6328
   Google Scholar
• Groves T. Report from BMJ post publication review meeting. Available from: http://www.bmj.com/rapid-response/2011/11/03/report-bmj-post-publication-review-meeting
   Google Scholar
• Henrotin YE. Interpretation of metaanalyses: pitfalls should be more widely recognized. J Rheumatol 2012;39:1107-9
   PubMed Web of Science ®Google Scholar
• Towheed TE, Anastassiades TP. Glucosamine and chondroitin for treating symptoms of osteoarthritis. JAMA 2000;283:1483-4
   PubMed Web of Science ®Google Scholar
• Strand V, Hochberg MC. Study design and outcome measures in osteoarthritis clinical trials. In: Moskowitz RW, Altman RD, Hochberg MC, Buckwalter JA, Goldberg VM (eds.) Osteoarthritis: Diagnosis and Medical/Surgical Management, 4th edn. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2007:313-25
   Google Scholar
• Hochberg MC, Zhan M, Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo controlled trials of chondroitin sulfate. Curr Med Res Opin 2008;24:3029-35
   PubMed Web of Science ®Google Scholar
• Malaise M, Marcolongo R, Uebelhart D, et al. Efficacy and tolerability of 800 mg chondroitin 4 & 6 sulfate in the treatment of knee osteoarthritis: a randomized, double-blind, multicentre study versus placebo. Litera Rheumatologica 1999;24:31-42
   Google Scholar
• Conrozier T. Anti-arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&6). Presse Med 1998;27:1862-5
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 2010;18(Suppl 1):S28-31
   PubMed Web of Science ®Google Scholar
• Bruyere O, Reginster JY. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007;24:573-80
   PubMed Web of Science ®Google Scholar